Johnson & Johnson's press release moved JNJ +1.33%
JNJ moved -0.13% in five minutes and +1.33% by market close — about 20.8× Johnson & Johnson's median close-day move.
· PR Newswire · Press release · Realized reaction, point-in-time, zero look-ahead.
New long-term data reinforces TREMFYA® (guselkumab) as the only IL-23 inhibitor proven to substantially inhibit structural joint damage in active psoriatic arthritis
Via PR Newswire
How JNJ reacted after the announcement.
| Horizon | Reaction | JNJ median |
|---|---|---|
| 30 sec | -0.21% | — |
| 1 min | -0.45% | — |
| 5 min | -0.13% | — |
| 10 min | +0.09% | — |
| 30 min | +0.65% | +0.06% |
| 60 min | +1.09% | — |
| 90 min | +1.08% | — |
| 120 min | +1.15% | — |
| to close | +1.33% | +0.06% |
- +1%
- 42 min
- +2%
- never traded
- +3%
- never traded
- +5%
- never traded
- -1%
- never traded
- -2%
- never traded
- -3%
- never traded
- -5%
- never traded
A hatched rung is a threshold the price never touched inside the measured window — not a missing measurement. Most news never moves a large-cap by 5% either way, so a mostly empty ladder is the finding, not a gap in the data.
| Held for | Return |
|---|---|
| D+1 | +1.94% |
| D+2 | +2.15% |
| D+3 | +3.44% |
| D+4 | +3.72% |
| D+5 | +4.15% |
| 1M | +9.39% |
| 3M | +24.29% |
| 6M | +17.89% |
| 12M |
Each row is measured from the price at the news to that horizon independently, so the ladder is not cumulative and a later row can sit above an earlier one. “Available” is a date, not a gap: that horizon has not elapsed yet for this event, and it is computed from the event’s own timestamp rather than from the data. An em dash is the other case — the horizon passed and no return was recorded.
Five minutes after the news, JNJ had moved -0.13%; by the close it stood at +1.33% — the two readings disagree in direction, and the early move did not survive to the close.
Impact: Positive. Reaction = percent move vs. the price at the news timestamp. Sources below.
JNJ’s news landed in the pre-market window; the main session closed +1.33%.
- Mainprior session
- After-hours4:00 – 8:00 PM
- Overnightno tape
- Pre-market4:00 – 9:30 AM
- Main session9:30 AM – 4:00 PM
Segment widths are fixed, so two events on different days sit in comparable places. Hatched segments are real elapsed time with no tape to measure — the overnight halt is not a gap in the data. This event carries no intraday receipt time, so it is not pinned to a minute.
| Window | What it answers | Anchor price | Result | vs S&P 500 |
|---|---|---|---|---|
| All | From the news to the first main-session close, across every session in between. | 195.78re-anchored to the first print after the news | +1.94% | — |
| After-hours | The move between the closing bell and the overnight halt. | — | not measured | — |
| Pre-market | The move between the pre-market open and the opening bell. | — | not measured | — |
| Main | The move inside the regular session, from the news to the close. | 196.96the price at the news | +1.33% | +1.94% |
The main-session result is measured upstream against the price at the news; the all-sessions result is computed here from its own anchor and close, so the two can differ in the last decimal. The adjusted column subtracts the S&P 500’s move over the same main-session span — there is no index anchor for the all-sessions span, so that cell stays empty rather than borrowing this one. After-hours and pre-market are measured upstream but populate on a small minority of events, so this page does not request them. Those rows are unmeasured, not empty.
The same event measured across every session8
| Horizon | Reaction |
|---|---|
| 30 sec | +0.08% |
| 1 min | +0.11% |
| 5 min | +0.01% |
| 10 min | +0.15% |
| 30 min | +0.13% |
| 60 min | +0.21% |
| 90 min | +0.47% |
| 120 min | +1.35% |
Where this JNJ event came from, and what the tape did with it.
Johnson & Johnson issued a press release, carried via PR Newswire, on Nov 17, 2025. It was one of 3 Johnson & Johnson headlines News Quantified labeled that day, so its measurement window overlaps with the others on a shared tape. The same session also carried Johnson & Johnson's "Johnson & Johnson Set to Revolutionize the Treatment of Cancer With…" and 1 other Johnson & Johnson headline, each measured on its own clock.
Against the price at the news timestamp, JNJ moved -0.13% after five minutes and +1.33% by the close — about 20.8× Johnson & Johnson's median close-day move of +0.06% across 2,000+ events. Because several releases shared that day, their measurement windows overlap and no single headline cleanly owns the move.
This is the alert you’d have received.
New long-term data reinforces TREMFYA® (guselkumab) as the only IL-23 inhibitor proven to substantially inhibit structural joint damage in active psoriatic arthritis
Track JNJ and you’ll get one email like this the next time it moves on news — the headline, the measured reaction, and how it compares to JNJ’s baseline. Nothing else.
Set up JNJ alerts →How this compares to JNJ’s usual reaction.
Across 2,000+ labeled events, JNJ’s median 30-minute reaction to all news is +0.06% (56% up); by the close it is +0.06%.
| Middle 50% of JNJ reactions | -0.26% to +0.39% |
|---|---|
| Median reaction (30-min) | +0.06% |
| This event | +0.65% |
| Measured reactions | 2,000+ |
Half of all Johnson & Johnson news events land between -0.26% and +0.39% at 30 minutes; this one is a single draw from that distribution.
You just saw one reaction. There are 26M+ more.
See the full JNJ reaction history →JNJ’s session ranged -0.54% to +1.68% against the price at the news.
7.7M shares against a 30-day average of 5M.
What the average share actually traded at across the session, rather than at any one print.
The close moved +1.33% against a 20-day average true range of 2.97. JNJ carries no market-cap or price-to-earnings figure on this record, and no short interest, so none is shown.
Email me when JNJ moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to JNJ's baseline. Nothing else.
How comparable JNJ events have landed.
Across 4 other recent Johnson & Johnson press release events, the median close-day reaction was -0.37%. Each is measured the same way, from its own news timestamp.
8 more JNJ events, each measured the same way.
Recent JNJ events, each with its measured reaction8
That same day, across the market6
Same measurement, same clock, different names — each headline measured from its own news timestamp, point-in-time.
Peer tickers, measured the same way4
Every US ticker is measured the same way, from its own news timestamp. Browse all tickers →
JNJ carried 2 other records that day.
Each was measured the same way, from its own timestamp.
| Record | Event | 5-min | To close |
|---|---|---|---|
| Johnson & Johnson Set to Revolutionize the Treatment of Cancer With the Acquisition of Halda Therapeutics | Press release | -0.13% | +1.33% |
| Vida Ventures Marks Fourth Major Portfolio Acquisition in 2025, Capping a Record-Setting Year for Its Science-Led, Discipline-Driven Strategy | Press release | +0.31% | +0.50% |
How the numbers are made.
How was JNJ's -0.13% reaction measured?
From the news timestamp, not the trading day: News Quantified takes the last trade before this press release as the base price and measures the move five minutes of trading later — point-in-time, zero look-ahead. The same clock produced the +1.33% to-close figure.
What is Johnson & Johnson's median reaction, and how does this event compare?
Johnson & Johnson's median is drawn from 2,000+ labeled events; at 30 minutes it sits at +0.06%, and +0.06% by the close. This event's move is one draw from that distribution — ordinary or outlier, the chart's median ticks show which.
3 Johnson & Johnson headlines shared Nov 17, 2025. Whose reaction is this?
Each of the 3 same-day Johnson & Johnson events is measured from its own timestamp, but their windows overlap on one tape, so we show the cluster rather than pretending a single headline owns the move.
Does +1.33% predict Johnson & Johnson's next reaction?
No. +1.33% is a realized fact about Nov 17, 2025, not a forecast. Past reactions describe a distribution; they say nothing certain about any future move.
How to cite this reaction.
News Quantified. "New long-term data reinforces TREMFYA® (guselkumab) as the only IL-23 inhibitor proven to substantially inhibit structural joint damage in active psoriatic arthritis." JNJ realized price reaction, Nov 17, 2025. Retrieved from https://newsquantified.com/tickers/jnj/news/new-long-term-data-reinforces-tremfya-guselkumab-as-only-il-2025-11-17
Canonical URL: https://newsquantified.com/tickers/jnj/news/new-long-term-data-reinforces-tremfya-guselkumab-as-only-il-2025-11-17
Query this dataset via the API & MCP →